Skip to main content

Advertisement

Table 1 Essential clinicopathological and molecular characteristics of the three breast cancer groups investigated.

From: Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases

  LS-associated breast cancers LS-associated breast cancers  
  Carriers Non-carriers Sporadic breast cancer c
No. of tumors 23 18 49
ductal 17 14 30
ductal in situ 2 1 -
lobular 3 - 19
other 1 2 -
no histological data - 1 -
Size (= 20 mm) 7/19 (37%) 9/14 (64%) 30/49 (61%)
G1 2/19 (11%) 4/12 (33%) 12/46 (26%)
G2 10/19 (53%) 5/12 (42%) 29/46 (63%)
G3 7/19 (37%) 3/12 (25%) 5/46 (11%)
Lymph node metastases 6/16 (38%) 7/10 (70%) 28/47 (60%)
Receptor status:    
ER-positivity 20/22 (91%) 6/7 (86%) 49/49 (100%)
PR-positivity 15/22 (68%) 5/7 (71%) 41/46 (89%)
HER2-positivity 3/20 (15%) 1/6 (17%) 0/49 (0%)
Average age at diagnosis (years) 56 54 61
MSI 8/23 (35%) 0/18 (0%) N/A
MMR protein reduced or lost 13/20 (65%) a 0/14 (0%) b 0/49 (0%) b
Average number of TSGs methylated out of 24 per tumor 2.3 2.0 2.4
  1. aFor MMR protein corresponding to the germline mutation; bfor any MMR protein investigated (MLH1, MSH2, MSH6); cClinicopathological data and MMR status reflect selection method used (see text). Note: All frequency calculations are based on tumors for which data were available or which could be successfully analyzed in the laboratory. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LS, Lynch Syndrome; MMR, mismatch repair; MSI, microsatellite instability; PR, progesterone receptor; TSG, tumor suppressor gene.